GSK
GSK
793 hedge funds and large institutions have $12.4B invested in GSK in 2021 Q3 according to their latest regulatory filings, with 75 funds opening new positions, 297 increasing their positions, 230 reducing their positions, and 69 closing their positions.
101% more call options, than puts
Call options by funds: $327M | Put options by funds: $163M
29% more repeat investments, than reductions
Existing positions increased: 297 | Existing positions reduced: 230
9% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 69
0.07% more ownership
Funds ownership: 5.08% → 5.14% (+0.07%)
1% less funds holding
Funds holding: 800 → 793 (-7)
3% less capital invested
Capital invested by funds: $12.7B → $12.4B (-$355M)
7% less funds holding in top 10
Funds holding in top 10: 14 → 13 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$136M |
| 2 |
Two Sigma Advisers
New York
|
+$131M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$77.5M |
| 4 |
BCIM
Black Creek Investment Management
Toronto,
Ontario, Canada
|
+$49.9M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$20.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Holdings
Tokyo,
Japan
|
-$155M |
| 2 |
CA
Capitolis Advisors
New York
|
-$60.7M |
| 3 |
Barclays
London,
United Kingdom
|
-$45.3M |
| 4 |
JEST
JTC Employer Solutions Trustee
St Helier,
Jersey
|
-$43.9M |
| 5 |
BCAM
Boston Common Asset Management
Boston,
Massachusetts
|
-$29.9M |
GSK Hedge Fund Activity: Q3 2021 in Review
793 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q3 2021, worth a combined $12.4B — down 2.8% from $12.7B a quarter earlier.
Buyers outnumbered sellers: 75 funds opened new GSK positions and 69 closed out — a net gain of 6 holders — while 297 added to existing stakes and 230 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $136M. The largest seller was Nomura Holdings, cutting an estimated $155M.
- 793 institutional investors held GSK (GSK) as of Q3 2021, down from 800 in Q2 2021.
- Funds reported $12.4B of GSK stock for Q3 2021, down 2.8% quarter-over-quarter.
- 75 funds opened new GSK positions in Q3 2021 and 69 closed out, a net change of +6 holders.
- The largest GSK buyer in Q3 2021 was Two Sigma Investments, an estimated $136M added.
- The largest GSK seller in Q3 2021 was Nomura Holdings, an estimated $155M sold.
Based on aggregated 13F filings for Q3 2021.